Latest Capital Management Strategies News

Senetas Corporation Limited successfully passed all resolutions at its 2025 Annual General Meeting, including director re-elections, executive option grants, and a capital return proposal.

GrainCorp Limited has declared a combined ordinary and special dividend of AUD 0.24 per share, fully franked, reflecting confidence in its recent financial performance.

Mount Gibson Iron has announced a further extension of its on-market share buy-back program, now set to run until November 2026, maintaining flexibility amid uncertain market conditions.

Flight Centre Travel Group delivered a record $24.5 billion total transaction value in FY25 alongside solid profitability, while setting an ambitious profit growth target for FY26 amid ongoing investments in AI and digital innovation.

VGI Partners Global Investments Limited has announced an on-market buy-back of its ordinary shares, set to begin in late November 2025 and run for a full year. The buy-back offers a flexible approach without fixed volume limits or a set price, signaling a strategic capital management move.

Garda Property Group is set to settle the sale of its North Lakes industrial property, freeing up $113.6 million to reduce debt and pursue new investments.

Carnavale Resources Limited has successfully completed a non-renounceable entitlement offer, raising approximately AUD 2.66 million through the issue of new shares, fully underwritten by Canaccord Genuity.

Nanosonics Limited has announced a $20 million on-market share buy-back program for FY26, underscoring its robust financial health and confidence in future growth driven by new product innovations.

QBE Insurance Group has priced a $300 million issue of USD subordinated notes due in 2037, offering investors a fixed 5.239% interest rate initially, with a reset in 2032 tied to U.S. Treasury yields. These notes strengthen QBE’s regulatory capital under APRA’s framework.

Harvey Norman Holdings has announced a further extension of its on-market share buyback program, allowing up to 10% of shares to be repurchased by November 2026, signaling continued confidence in its capital management strategy.

Chimeric Therapeutics has progressed its CHM CDH17 and CHM CORE-NK clinical trials with promising safety and efficacy signals, while securing a key manufacturing partnership and appointing a renowned haematologist to its board. However, the company faces a pressing cash runway challenge.

Wesfarmers Limited has announced a fully franked special dividend of AUD 0.40 per share alongside a substantial AUD 1.10 capital return, both payable on 4 December 2025, marking a significant milestone in its 2025 capital management strategy.